Differences

This shows you the differences between two versions of the page.

--- content:fires [2020/02/14 17:38] – [Treatment] icna
+++ content:fires [2020/02/14 17:47] – [Treatment] icna
@@ Line 47: / Line 47: @@
   * The efficacy of ketogenic diet as an alternative to pharmacotherapy in FIRES has been reported with favourable outcomes[(:cite:20813015>{{pubmed>short:20813015}})][(:cite:19191829>{{pubmed>short:19191829}})]. There are no randomized controlled trials available on the use of the ketogenic diet in status epilepticus[(:ref:todo)].
   * Deep brain stimulation of the centromedian thalamic nuclei (CMN-DBS) has been reported in some cases with where generalised seizures have been abolished but did not have a lasting effect on focal seizures burden[(:cite:31446001>{{pubmed>short:31446001}})]
-  * There are also case reports on the use of Anakinra (a recombinant version of the human interleukin-1 receptor antagonist) in FIRES but with variable outcomes[(:cite:31446001>{{pubmed>short:31446001}})]
+  * There are also case reports on the use of [[Anakinra]] (a recombinant version of the human interleukin-1 receptor antagonist) in FIRES but with variable outcomes[(:cite:31446001>{{pubmed>short:31446001}})]
   * Gofshteyn et al.(2017) reported an open label case series where cannabadiol (Epidiolex, GW Pharma) was used alongside other anti-seizure medications on emergency or expanded investigational protocols in either the acute or chronic phase of illness and showed improvement in seizure frequency and duration[(:cite:27655472>{{pubmed>short:27655472}})]
 ==== References ====